Articles of note for people dealing with pituitary disease and related conditions.
The latest from pharmaceutical companies and healthcare organizations
Brief, insightful commentary from Dr. Lewis Blevins on issues of relevance to pituitary disease.
Game Changers: An AI Facial Recognition System that detects acromegaly 10 years before diagnosis
Could artificial intelligence and machine learning recognize the early, subtle changes in people’s faces associated with the hormonal disease acromegaly? New research spearheaded by Dr. Manel Puig-Domingo and outlined in a recent paper published in the journal PITUITARY raises the possibility that AI algorithms and machine learning could provide a game-changing approach to the early diagnosis of this complex disease, which now takes an average of 6 to 10 years to diagnose.
Dr. Naila Goldenberg speaks about Adrenal Insufficiency and her experiences with cortisol pumps
There is growing interest in the use of cortisol pumps to treat patients with adrenal insufficiency, though most physicians in the US lack experience in this area. Dr. Lewis Blevins caught up with Dr. Naila Goldenberg at The Endocrine Society Meeting in San Francisco, California, in July 2025.
Worth noting:
From Crinetics Pharmaceuticals – FDA approves Crinetics PALSONIFY™ for adults with acromegaly . Read more
Recordati announces FDA approval of ISTURISA® new indication in the U.S. to treat endogenous hypercortisolemia in patients with Cushing’s syndrome,- Learn more here
Corcept Therapeutics announces FDA Relacolirant new drug application to treat Hypercortisolism . Read more
Camurus announces final results for the once-monthly octreotide subcutaneous treatment option for acromegaly. Read more
New support site from Chiesi; Rethink acromegaly
Pfizer announces Together with Acromegaly patient support site.
Chiesi relaunches a patient-facing website for Mycapssa.
Content for physicians and healthcare professionals.
Join a drug trial. Find out how. Here’s a partial list of studies.
Latest trends and a roundup of health and wellness news
Endo 2025 interviews; conversations with advocates, nurses, and specialty pharmacy executives
This week we bring you my chats from ENDO 2025 with Jill Sisco, president of the Acromegaly Community, Dr. Chris Yedinak, retired professor at Oregon Health and Science University, adjunct professor at Mount Marty University, and Alan Erck, Chief Commercial Officer at Anovo Pharmacy. Learn their outlook for patient care and support.
From Endo 2025, Amplifying Expert Voices: my conversation with our friends from Recordati Rare Diseases
We caught up with a group of top executives at Recordati at ENDO 2025 and asked them about their plans, challenges and opportunities and, importantly, their outlook for new therapies in acromegaly and Cushing’s.
Perspectives from inside Endo 2025 – My chats with Crinetics Pharmaceuticals’ Jacqui Kirby, Stephanie Kallay, and Dr. Peter Trainer
Through our conversations with leading pituitary experts, physicians, nurses, industry executives, researchers, patient advocates, and other key stakeholders, we gain unique insights from the fascinating world of pituitary disease research and treatment.
Dr. Naila Goldenberg speaks about Adrenal Insufficiency and her experiences with cortisol pumps
There is growing interest in the use of cortisol pumps to treat patients with adrenal insufficiency, though most physicians in the US lack experience in this area. Dr. Lewis Blevins caught up with Dr. Naila Goldenberg at The Endocrine Society Meeting in San Francisco, California, in July 2025.
The Podcast
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D. Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Live Talk on Demand
In today’s podcast, Dr. Lewis Blevins dives into the fascinating findings from a study by Corcept Therapeutics on the prevalence of hypercortisolism in people with type 2 diabetes.
Apple Podcasts
Spotify
Amazon Music
Google Podcasts
